Spotlight On... Sun sales in U.S. fall further as FDA issues linger; Novo A/S CEO to step down; Alnylam plots new $200M manufacturing plant; and more...

India's Sun Pharmaceutical saw its sales in the U.S., its largest market, continue to fall as problems with a key plant in India have yet to be resolved. U.S. sales were off 11% to $486 million in the quarter ended Dec. 31, 2015, India's largest drugmaker reported today. It did, however, benefit from its U.S. subsidiary, Taro, which saw revenues increase 9% to $258 million. Sources are telling Indian media that the drugmaker is also looking to unload a couple of plants in India that it picked up in its $4 billion buyout last year of Ranbaxy Laboratories. Earnings report (PDF) | Story | More

@FiercePharma: Startup aims to match ailing pets with clinical trials that could help people, too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Qualicaps snags Brazil's largest hard capsule maker. Will expand in Latin America from there. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales. Article | Follow @CarlyHFierce

> Eivind Kolding, CEO of Novo A/S, Novo Nordisk's ($NVO) parent, is stepping down after less than two years in the position. Report

> RNAi biotech Alnylam Pharmaceuticals ($ALNY) plans to shell out $200 million on a manufacturing plant in a bet that its pipeline therapies will advance to market. More

Medical Device News

@FierceMedDev: Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma shells out big campaign dollars to presidential candidates. FiercePharma article | Follow @EmilyWFierce

> GV charts its own course with big bets on med tech: Bloomberg. Story

> SI-Bone's spinal fusion implant gains near-total Medicare coverage on back of strong studies. Article

Biotech News

@FierceBiotech: Novartis buys EU rights to Pfizer's Remicade biosimilar, targeting Merck. Report | Follow @FierceBiotech

@JohnCFierce: Google cool: I spend no time fundraising," Maris tells . "Alphabet can give us as much $$ as we want. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Early theme in responses to this poll: Men much more likely to get "stretch" jobs, be lauded for ambitious failures. ICYMI from FierceBiotech | Follow @DamianFierce

> Alnylam bets $200M on its commercial future with new plant. News

> U.K.'s Shield pulls off an IPO but dramatically cuts its flotation price. Article

> Apellis raises $47M after pulling the plug on an $86M IPO. Report

And Finally... A Boston University study found the rate of dementia cases in Europeans has been decreasing, possibly because of healthier lifestyles. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.